Vibe-decoding the White House-Anthropic fight over Fable

CEO of Anthropic Dario Amodei attends a working lunch with G7 leaders, G7 outreach partners, and global tech CEOs on innovation and AI, during the G7 Summit on June 17th, 2026, in Evian-les-Bains, France. | Photo: Anna Moneymaker / Getty Images Hello and welcome to Regulator, an email for Verge subscribers about technology, politics, and what happens when science crashes headlong into self-interest. Not a subscriber? Sign up here today! Got the scoop on a petty feud that's going to somehow fundamentally reshape the entire field of frontier AI development? Send 'em over to tina.nguyen+tips@theverge.com. Back when I was covering Donald Trump's first presidency, it was incredibly common to read three different versions of the same story. His administration had split into several factions, all of which had different interests, and all of which hated each other. There was the Reince Pr … Read the full story at The Verge.

Key Takeaways

•CEO of Anthropic Dario Amodei attends a working lunch with G7 leaders, G7 outreach partners, and global tech CEOs on innovation and AI, during the G7 Summit on June 17th, 2026, in Evian-les-Bains, France

•This story was reported by The Verge AI, covering developments in the news space.

•AI advancements continue to reshape industries — read the full article on The Verge AI for complete coverage.

Vibe-decoding the White House-Anthropic fight over Fable

Key Takeaways

Related Articles

The only AI glossary you’ll need this year

Anthropic wants to develop its own drugs

A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered

Takeda signs US$600M AI drug discovery deal with Insilico

Discussion

Vibe-decoding the White House-Anthropic fight over Fable

Key Takeaways

Related Articles

The only AI glossary you’ll need this year

Anthropic wants to develop its own drugs

A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered

Takeda signs US$600M AI drug discovery deal with Insilico

Discussion

Related Articles

TechCrunch AI
The only AI glossary you’ll need this year
The rise of AI has brought an avalanche of new terms and slang. Here is a glossary with definitions of some of the most important words and phrases you might encounter.

The Verge AI
Anthropic wants to develop its own drugs
At the event "The Briefing: AI for Science" earlier this week, Anthropic announced Claude Science, a new "AI workbench for scientists" that pulls fragmented tools and datasets into one environment, and generates figures and visuals. Anthropic, already dominating the industry with its popular coding

The Verge AI
A behind-the-scenes look at Midjourney’s medical scanner leaves many questions unanswered
A scan of an imaging phantom, segmented to validate how cleanly structures separate under controlled conditions. | Image: Midjourney Medical Midjourney has shown more of its futuristic medical scanner. It still hasn't shown much proof it works. The AI startup, best known for generating images, re

AI News Daily
Takeda signs US$600M AI drug discovery deal with Insilico
Takeda has entered a strategic collaboration with Hong Kong-based Insilico Medicine to use AI in early-stage drug discovery across the Japanese pharmaceutical company’s therapeutic areas. The companies did not disclose which therapeutic areas or disease targets will be covered under the collaboratio